Stocks · News reference
On September 23, 2026, REGENXBIO Inc. (the "Company") and The Trustees of the University of Pennsylvania ("UPenn") entered into a Settlement Agreement (the "Settlement Agreement") with Sarepta
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Regenxbio (NASDAQ:RGNX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to
Mizuho analyst Graig Suvannavejh initiates coverage on Regenxbio (NASDAQ:RGNX) with a Outperform rating and announces Price Target of $22.
Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional
Cramer called Sarepta controversial, praised Avery Dennison and Ciena, favored ING and Santander, and declined to endorse FirstCash.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.